Insider Sale Notice: Chemed 2,000 Shares via Merrill Lynch

Rhea-AI Filing Summary

Form 144 notice for Chemed Corporation (CHE) shows proposed sales of common stock tied to awards granted in 2022. The filing names Kevin McNamara as the seller and lists Merrill Lynch as the broker. It records two stock awards of 1,000 shares each acquired on 05/02/2022 and 08/18/2022 through stock exercise, and indicates an intended sale of 2,000 shares with an aggregate market value of $857,107. The form also records a sale by Kevin McNamara of 2,000 shares on 08/05/2025. The filer attests there is no undisclosed material adverse information and includes the standard signature and legal warnings.

Insights

Securities Analyst

TL;DR: Routine insider filing showing disposition of equity awards; no earnings or material corporate events disclosed.

This Form 144 documents an insider's proposed sale of company stock originating from 2022 stock awards exercised in May and August 2022. The amounts involved (2,000 shares; aggregate market value shown at $857,107) reflect a personal liquidity event rather than a corporate action. There is no new operational, financial, or governance information in the filing; its investor impact is limited to share supply considerations and insider sentiment signals.

Compliance/Risk Analyst

TL;DR: Compliance filing appears complete and standard; includes required attestations and broker details.

The notice includes broker identification (Merrill Lynch) and acquisition details for each block of awarded shares, which supports Rule 144 compliance. The seller represents no undisclosed material adverse information, and the filing contains the usual legal warning about misstatements. From a compliance standpoint, the filing provides the necessary traceability of acquisition dates and sale intent; it does not indicate regulatory or governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Chemed Corporation	Merrill Lynch 5905 E.Galbraith Rd Suite 7000 Cincinnati OH 45236	2000	857107	0	09/26/2025	SEC

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/02/2022	Stock Award	Chemed Corp			1000	05/02/2022	Stock Exercise
Common	08/18/2022	Stock Award	Chemed Corp			1000	08/18/2022	Stock Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kevin McNamara 255 E 5th St Ste 2600 Cincinnati OH 45206	Chemed Corp	08/05/2025	2000	857107

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Chemed (CHE) Form 144 disclose about the seller?

The filing names Kevin McNamara as the person for whose account the securities are to be sold and provides his address as shown in the form.

How many Chemed shares are proposed for sale and what is the aggregate value?

The form lists a proposed sale of 2,000 shares with an aggregate market value of $857,107.

When were the shares being sold originally acquired?

The shares were acquired as stock awards on 05/02/2022 (1,000 shares) and 08/18/2022 (1,000 shares), both noted as stock exercise transactions.

Who is the broker handling the sale in the Form 144?

The broker listed is Merrill Lynch at the address provided in the filing.

Does the filing report any undisclosed material information about Chemed?

The filer attests by signature that they do not know of any material adverse information regarding the issuer that has not been publicly disclosed.